The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Key information relevant to the recruitment process for the
overall study, such as dates of the recruitment period and locations

From February 2002 to May 2006, youth were screened at four academic sites: University of North Carolina at Chapel Hill, McLean Hospital and Cambridge Health Alliance at Harvard Medical School, University of Washington, and Case Western Reserve University.

Pre-Assignment Details

Significant events and approaches for the overall study
following participant enrollment, but prior to group assignment

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

We are referring to the population of participants who had baseline assessment, took at least one dose of trial medication, and had at least one post-baseline assessment. There were 3 randomized subjects, on in each treatment group, who did not take at least one dose of study medication and are not included.

Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks

Measure Description

Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores > that 60 are considered clinically significant.

Time Frame

8 weeks

Population Description

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.

Reporting Groups

Description

Olanzapine

oral olanzapine 5-20mg per day for up to 52 weeks

Risperidone

oral risperidone 0.5mg to 6mg daily for up to 52 weeks

Molindone

oral molindone from 10-140mg/daily for up to 52 weeks

Measured Values

Olanzapine

Risperidone

Molindone

Participants Analyzed [Units: Participants]

35

41

40

Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks [Units: Units on a scale]Mean (Standard Deviation)

-26.6 (17.8)

-23.7 (25.5)

-27.0 (17.7)

Statistical Analysis 1 for Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks

Groups [1]

All groups

Statistical Test Type [2]

Superiority or Other

Statistical Method [3]

Mixed Models Analysis

P Value [4]

0.05

[1]

Additional details about the analysis, such as null hypothesis and power calculation:

No text entered.

[2]

Details of power calculation, definition of non-inferiority margin, and other key parameters:

No text entered.

[3]

Other relevant method information, such as adjustments or degrees of freedom:

No text entered.

[4]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance: